Clinical Trial

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * Sacituzumab govitecan (Trodelvy™;IMMU-132) * Pembrolizumab (Keytruda®; MK-3475)
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-04-01 -> 2027-04-01 2026-04-30
Trial Details
NCT Number NCT04468061
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Gilead Sciences, Merck Sharp & Dohme LLC
Conditions Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
Enrollment 110 participants
Start Date 2020-07-20
Primary Completion 2027-04-01 (estimated)
Study Completion 2029-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-29